Inovio Pharmaceuticals, Inc. Aktie News

PLYMOUTH MEETING, Pa. , Nov. 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences: Piper Sandler 37th Annual Healthcare Conference (New York, NY) Date...

Inovio Pharmaceuticals (INO) reported a disappointing 3Q25 with a GAAP EPS loss of -$0.87, missing consensus by $0.45 and triggering a 12% stock slide. INO ended the quarter with $50.8 million in cash, expects a runway into 2Q26, and announced a $25 million public offering to support operations. Key pipeline progress includes completion of the BLA submission for INO-3107, with hopes for FDA pri...

PLYMOUTH MEETING, Pa. , Nov. 11, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 13,158,000 shares of its common stock at a public offering p...

Inovio Pharmaceuticals, Inc. ( INO ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Jennie Willson Jacqueline Shea - CEO, President & Director Michael Sumner - Chief Medical Officer Steven Egge - Chief Commercial Officer Peter Kies - Chief Financial Officer Conference Call Participants Edward Tenthoff - Piper Sandler & Co., Research Division Jay Olson - Oppenheimer & C...

PLYMOUTH MEETING, Pa. , Nov. 10, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review Expect to receive file acceptance by year end 2025 with potential PDUFA date in mid-2026 if request for priority review granted Commercial preparations continuing for potential launch in mid-2026 if INO-3107 is approved by FDA Results from Phase 1 ...

Recurrent respiratory papillomatosis (RRP) is a rare HPV-related disease of the respiratory tract with significant unmet need INO-3107 previously received Orphan Drug and Breakthrough Therapy designations; BLA submitted under FDA's Accelerated Approval program Expect to receive file acceptance by year end 2025 with potential PDUFA date in mid-2026 if request for priority review granted PLYMOUTH...

PLYMOUTH MEETING, Pa. , Oct. 31, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").